ATTAIN-1 provides large, randomized evidence that daily oral orforglipron reduced body weight more than placebo over 72 weeks in adults without diabetes. Its highest investigational-dose group lost an estimated 11.2% of starting weight on average, compared with 2.1% with placebo. That is a substantial treatment difference, but interpreting it requires more than reading the largest number: the population, missing measurements, treatment discontinuation, and exact formulation all matter.
Orforglipron is now FDA approved in the United States as Foundayo, with initial approval in 2026. The trial’s investigational dose names are not current marketed tablet strengths. This analysis uses the indexed primary research abstracts and available official material, including the full DailyMed prescribing label and FDA safety information; it does not imply examination of every research protocol or supplement. The central distinction is between evidence about a medicine under trial conditions and promises made by a commercial provider.
At a glance
- Trial design
- ATTAIN-1 randomized 3,127 adults without diabetes to three daily oral orforglipron groups or placebo for 72 weeks, with lifestyle intervention.
- Primary published result
- Mean weight change was −7.5%, −8.4%, and −11.2% in the investigational 6-, 12-, and 36-mg groups, respectively, versus −2.1% with placebo.Sources: [1]
- Response varied
- In the investigational 36-mg group, 54.6% reached at least 10% weight loss and 18.4% reached at least 20%; these are overlapping thresholds.Sources: [1]
- Tolerability affected treatment
- Adverse events caused treatment discontinuation in 5.3%–10.3% of orforglipron participants versus 2.7% receiving placebo.Sources: [1]
- Formulation matters
- Foundayo’s official label describes evidence from an investigational formulation expressed as equivalent marketed dosages. Trial milligram amounts are not interchangeable with marketed tablet strengths.Sources: [2]
What the randomized comparison actually tested
ATTAIN-1 was a multinational, phase 3, double-blind trial funded by Eli Lilly. Participants were assigned in a 3:3:3:4 ratio to once-daily oral orforglipron at investigational doses of 6, 12, or 36 mg, or to placebo. Double blinding concealed assignment, while randomization helped balance measured and unmeasured starting characteristics. The larger allocation to placebo supplied a common comparison group for all three active arms.
Both active-treatment and placebo participants received lifestyle intervention. The question was therefore whether adding orforglipron improved outcomes beyond the trial’s background diet and physical-activity program—not whether medication outperformed no care. The primary endpoint was percentage change in body weight from baseline to week 72.
An endpoint is the specific outcome a study is designed to evaluate. Here it was weight change, not survival, heart attack prevention, or remission of another disease. Trial size and blinding strengthen the weight-loss comparison, but they do not turn a weight-management trial into an outcomes trial for every obesity-related condition.
Who participated—and who was outside the study
The indexed abstract summarizes the population as adults with obesity without diabetes. The official label gives more detailed eligibility: Trial 1, identified by the same registration number, enrolled adults with BMI of at least 30, or BMI from 27 to below 30 plus a weight-related condition. BMI is weight in kilograms divided by height in meters squared; it is an eligibility measure, not a complete description of health.
The label reports a mean starting weight of 103.2 kilograms and mean BMI of 37. Participants averaged 45 years old, 64% were female, and the age range was 18–88. Hypertension was present in 40%, dyslipidemia in 39%, and obstructive sleep apnea in 11%. These characteristics help readers assess resemblance to the studied population without assuming identical individual responses.
Type 2 diabetes was excluded from ATTAIN-1. The label separately describes a diabetes trial, so results from that population should not be silently folded into ATTAIN-1. Likewise, having some participants with sleep apnea or cardiovascular disease does not establish a condition-specific benefit. As the separate ESSENCE liver-evidence analysis illustrates, the clinical question depends on the population and endpoint actually tested.
STUDY DATA · GLP-1 Provider Brief
ATTAIN-1: mean weight change with the studied oral formulation
Randomized, double-blind trial of 3,127 adults with obesity without diabetes. Primary treatment-regimen estimand in the intention-to-treat population; all arms received healthy-diet and physical-activity support. Whiskers show 95% confidence intervals for each arm mean.
| Study group | Change from baseline body weight at week 72 (%) |
|---|---|
| Orforglipron study arm: 6 mg | -7.5 |
| Orforglipron study arm: 12 mg | -8.4 |
| Orforglipron study arm: 36 mg | -11.2 |
| Placebo | -2.1 |
Study-arm milligrams identify the investigational formulation, not current Foundayo tablet strengths or dosing instructions. These are group estimates, not individual predictions. Adverse events caused discontinuation in 5.3%–10.3% across active arms versus 2.7% with placebo. No injectable or other oral drug was the randomized comparator. Funded by Eli Lilly.
Original visualization of published aggregate data. No individual prediction or provider performance is represented. Original research ↗
Reading the average weight-loss estimates
All three investigational orforglipron groups had greater mean weight reduction than placebo. The published primary results are shown below, retaining the research formulation’s dose identifiers. These amounts identify study arms; they are not instructions for using Foundayo or another product.
Subtracting the placebo change from each active-group change gives additional average reductions of 5.4, 6.3, and 9.1 percentage points. These are differences between percentage changes, not relative risk reductions. For a purely illustrative starting weight of 100 kilograms, an 11.2% reduction corresponds to 11.2 kilograms, whereas 2.1% corresponds to 2.1 kilograms. That arithmetic explains scale; it does not predict an individual result.
The 95% confidence intervals describe statistical uncertainty around each group’s estimated mean. They do not describe the range containing 95% of individual participants’ outcomes. Nor should subtracting the endpoints of two group intervals be used to manufacture a confidence interval for their difference; that requires the comparison’s own statistical calculation.
| Study arm | Mean body-weight change | 95% confidence interval |
|---|---|---|
| Orforglipron 6 mg | −7.5% | −8.2% to −6.8% |
| Orforglipron 12 mg | −8.4% | −9.1% to −7.7% |
| Orforglipron 36 mg | −11.2% | −12.0% to −10.4% |
| Placebo | −2.1% | −2.8% to −1.4% |
Why the analysis method changes the headline
The primary report used a treatment-regimen estimand in the intention-to-treat population. An estimand defines the treatment effect the analysis aims to measure. Intention-to-treat keeps participants within their randomized assignments; the treatment-regimen approach addresses assignment to the regimen rather than restricting attention to people who remained continuously on treatment.
This is why the published 11.2% result should anchor discussion of the highest investigational arm’s primary outcome. An efficacy-oriented estimate answering a different adherence-related question is not interchangeable with the primary treatment-regimen result. A larger headline number should not replace it without explaining the different question being answered.
Missing data remain important. The label reports that week-72 weight measurements were missing for 24% of placebo participants and 14%–16% across active groups. Its analysis used multiple imputation—statistical estimation of missing values using observed participant data. Overall trial-drug discontinuation was 22%–24% in active groups and 30% with placebo. These figures are distinct from discontinuation specifically caused by adverse events, and they show why analysis assumptions matter.
Threshold results reveal more than the average
In the investigational 36-mg group, 54.6% reached at least 10% weight loss, 36.0% reached at least 15%, and 18.4% reached at least 20%. The corresponding placebo proportions were 12.9%, 5.9%, and 2.8%. These outcomes show that substantial responses occurred more often with active treatment, while also making clear that not everyone reached the same threshold.
The thresholds overlap. A participant losing 21% counts in all three categories, so adding the percentages would double- or triple-count people. The calculated active-versus-placebo differences are 41.7 percentage points for at least 10% loss, 30.1 points for at least 15%, and 15.6 points for at least 20%.
Threshold data also prevent a common misreading of the mean: an average reduction near 11% does not mean most participants lost exactly 11%. Conversely, approximately 45% of the highest investigational-dose group did not reach 10% loss under the reported analysis. The abstract does not establish which individual characteristics reliably predicted reaching each threshold.
Foundayo approval does not make the trial doses interchangeable
The DailyMed label identifies Foundayo as an FDA-approved oral orforglipron product with initial US approval in 2026. Its indication covers weight reduction and long-term weight maintenance in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. The abstract’s historical description of orforglipron as investigational is not the product’s current regulatory status.
The official label explicitly states that the pivotal evidence came from an investigational formulation and presents those data as equivalent Foundayo dosages. Consequently, the research doses of 6, 12, and 36 mg are not current tablet-strength names and must not be treated as milligram-for-milligram substitutes. No individual dose conversion follows from this article.
The label’s Trial 1 estimates are slightly different from the indexed report: for example, its highest-group mean is −11.1%, versus −11.2% in the abstract. This analysis preserves each source’s figures rather than splicing them together; the accessible material does not fully resolve the small difference. For evaluating a commercial description, the product-terms guide helps separate a product’s identity from broad oral GLP-1 marketing.
Gastrointestinal effects were common, and some people stopped treatment
The ATTAIN-1 abstract identifies gastrointestinal effects as the most common adverse events, usually mild or moderate. Adverse events of any type led to treatment discontinuation in 5.3%–10.3% of active-treatment participants versus 2.7% with placebo. The abstract does not assign each percentage in that range to a specific arm, and it does not say every discontinuation was gastrointestinal.
The label supplies broader safety detail from pooled Trials 1 and 2, including participants with and without diabetes. In that pooled population, gastrointestinal reactions occurred in 60%–69% across active groups versus 37% with placebo. Nausea occurred in 26%–35% versus 10%, and vomiting in 13%–24% versus 4%. These pooled rates should not be relabeled as ATTAIN-1-only findings.
The label reports severe gastrointestinal reactions in approximately 3% with orforglipron versus 1% with placebo, and more nausea, vomiting, and diarrhea during dose escalation than later treatment. Interpretation: tolerability and access to clinical assessment belong alongside expected weight change when evaluating a care arrangement. A support-pathways review can help distinguish medical follow-up from billing support without assuming either reproduces trial monitoring.
Less common risks require the official label
Foundayo carries a boxed warning concerning thyroid C-cell tumors. The nuance matters: other GLP-1 receptor agonists active in rodents produced these tumors, whereas orforglipron is not pharmacologically active in rats or mice and was reported as non-carcinogenic in the rodent studies. The human relevance of receptor-dependent rodent findings remains undetermined. Foundayo is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
The label also addresses pancreatitis, severe gastrointestinal reactions, kidney injury associated with volume depletion, gallbladder disease, and serious hypersensitivity. In pooled Trials 1 and 2, acute kidney injury was reported in 0.2% with active treatment versus 0.05% with placebo. Gallstones were reported in 1% versus 0.7%, and acute cholecystitis in 0.4% versus 0.3%. These are different events, not one combined complication rate.
Six pancreatitis events were adjudicated in six active-treatment patients, versus two events in one placebo patient; the label reports exposure-adjusted rates of 0.14 versus 0.04 patients per 100 years of exposure. Those units are not percentages. Rare events, pregnancy uncertainty, drug interactions, and delayed gastric emptying also explain why an oral route should not be equated with an absence of systemic risk.
Other trials answer different comparison questions
ATTAIN-1 also reported improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol relative to placebo. These are meaningful measurements, but they do not themselves establish fewer cardiovascular events. The label identifies several cardiometabolic analyses as not controlled for multiple comparisons, making their statistical interpretation different from the primary weight endpoint.
OASIS 4 provides separate evidence for oral semaglutide, not a direct comparison with orforglipron. Funded by Novo Nordisk, it randomized 307 adults without diabetes in a 2:1 ratio to daily oral semaglutide 25 mg or placebo plus lifestyle intervention. Within a 71-week study, its weight endpoint was measured at week 64: −13.6% versus −2.2%, a difference of −11.4 percentage points with a 95% confidence interval of −13.9 to −9.0. Gastrointestinal events occurred in 74.0% versus 42.2%.
The numerically larger OASIS 4 weight reduction does not establish superiority over orforglipron because participants were not randomized between those drugs. SURMOUNT-5 did directly compare two medicines, but both were weekly subcutaneous injections, not oral products. The SURMOUNT-5 analysis explains that distinct comparison. Neither study resolves how the two oral products would compare under one shared protocol.
| Trial | Intervention and comparator | Key distinction |
|---|---|---|
| ATTAIN-1; 3,127 participants | Daily oral investigational orforglipron versus placebo | Primary weight endpoint at 72 weeks |
| OASIS 4; 307 participants | Daily oral semaglutide 25 mg versus placebo | Weight endpoint at week 64 within a 71-week study |
| SURMOUNT-5; 751 participants | Weekly injected tirzepatide versus injected semaglutide | Open-label direct comparison at 72 weeks; neither treatment oral |
Trial evidence and provider contracts remain separate
ATTAIN-1 did not randomize participants between commercial platforms, pharmacies, memberships, or billing arrangements. Its clinical estimates therefore cannot validate a provider’s outcomes. Nor do results transfer automatically to compounded products, alternative formulations, or a different route of administration. FDA notes that unapproved GLP-1 products do not undergo its premarket review for safety, effectiveness, and quality.
Editorial interpretation: three documentary questions follow from the evidence. What exact product is being described? What clinical follow-up is included? What financial obligations continue if treatment changes? The enrollment-terms guide provides a framework for those questions. A trial’s 72-week observation period is not evidence that a commercial membership guarantees that duration of medication access or care.
For provider-specific documents, the CoreAge Rx review and Mochi Health review can be used to check written contract terms. These links do not imply either provider offers Foundayo, delivers condition-specific care, or achieves ATTAIN-1 outcomes. Clear documents can clarify obligations; they cannot substitute for evidence about the dispensed formulation or an individual’s response.
Questions & answers
Does 11.2% average weight loss mean that is the expected result for everyone?
No. It is an estimated group mean under the primary treatment-regimen analysis. The threshold results show substantial variation: 54.6% in the highest investigational-dose group reached at least 10% loss, while 18.4% reached at least 20%. Neither the mean nor its confidence interval gives an individual forecast.
Why are the trial’s milligram amounts different from Foundayo tablet strengths?
The pivotal trial used an investigational formulation. The official label expresses its evidence using equivalent marketed dosages, whose strength names differ from the research arms. The research amounts are identifiers, not instructions or a conversion chart. Product-specific prescribing information and clinical review govern use of the approved formulation.
Did ATTAIN-1 show that orforglipron prevents heart attacks?
No such conclusion follows from its reported weight endpoint and cardiometabolic measurements. Lower blood pressure or improved lipid levels are not the same outcome as fewer heart attacks, strokes, or deaths. Establishing those benefits requires evidence designed to measure the relevant clinical events.
Does OASIS 4 prove oral semaglutide works better?
No. OASIS 4 and ATTAIN-1 used separate populations, protocols, and endpoint timing. Each supports comparison with its own placebo group. A reliable oral-drug superiority claim would require an appropriate direct comparison rather than ranking averages from different trials.
What remains uncertain after 72 weeks?
The primary result does not establish an individual's longer-term course, response after discontinuation, or comparative benefit against another oral medicine. Rare harms also remain difficult to characterize precisely in a single trial. Continued evidence and official safety updates matter even when the randomized weight-loss finding is convincing.
Our assessment
ATTAIN-1 offers persuasive randomized evidence of greater average weight loss with daily oral orforglipron than placebo over 72 weeks. Its strongest interpretation preserves the primary treatment-regimen result, acknowledges variable response and treatment discontinuation, and keeps the investigational formulation distinct from marketed Foundayo strengths. Approval supports use within the current label; it does not erase safety considerations or establish superiority over another oral treatment. Editorially, the appropriate commercial takeaway is to verify product identity, clinical responsibilities, and contractual obligations—not to treat a trial average as a provider guarantee.
Sources & documentation
Scientific and official sources consulted October 21, 2026. Study findings apply to the populations, products and time periods described; they are not provider outcome data.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. ↗
- DailyMed - FOUNDAYO- orforglipron tablet, film coated ↗
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. ↗
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. ↗
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗